Get started

Community ideas

NAS100US- NQ- Scalping- LongBased on Friday’s price action, the Nasdaq has a scalping opportunity on the long side. This setup is contingent on the price accepting above the identified zone, which could indicate a short-term upward move ideal for scalpers. You need to see Confirmations. Disclaimer: This analysis is for informational purposes only and does not constitute financial advice. Scalping and trading carry significant risks, including the potential for substantial losses. Always exercise caution and trade responsibly.
OANDA:NAS100USDLong
by Bilind-GeniusScalper
1
Last Cycle -> This CycleNo two cycles have ever been exactly the same and it remains to be seen if that will ever happen. Bitcoin has thus far demonstrated a certain amount of cyclicity and predictable behavior on a 4-year time scale that has been widely studied and written about. Given BTC's overall influence on the asset class, we'll make the assumption in this idea that ADA can also exhibit a certain amount of cyclicity and predictable behavior within a similar time period. I'll start by defining 4, temporal 'parts'. From cycle to cycle they do NOT translate exactly and it's possible I'll look back in two years and realize I drew them wrong. Regardless of this, let's explore. ~~ Part 1 - The premature "Rally" The rhetoric of "This time is different" and "We're going to see new ATH's next month" are particularly strong. This "Rally" usually starts towards the end of the pre-halving year or sometime early in the halving year. Positive USD price movements set the stage for a short staged, preliminary mania before the inevitable lull. ~~ Part 2 - The Pre-Parabolic lull After seeing a 2x - 6x return from the cycle bottom, which is usually quite nice given years of mostly weekly red candles, a summer or late fall lull sets in. The rhetoric of "Crypto is dead" and "It's never going to go up again" emerge. The prior cycle, at least for ADA, appeared to be much shorter than this cycle's early new ATH ~6 months ago for BTC. Given bitcoin had a long cooling off period time year, it's not particularly shocking that ADA did as well. ~~ Part 3 - The first kickoff and the 35% downwick Cue the US elections and like clockwork the asset class kicks off. BTC breaks 100k for the first time, ADAUSD skyrockets from ~$0.30 to ~$1.30. IF YOU TAKE NOTHING ELSE FROM THIS POST AT LEAST CONSIDER THIS: ADAUSD, like ETHUSD, does not exactly have a great December track record during the halving year. Last Cycle, ADAUSD saw a -35% downwick from the local high to the local bottom. Ask yourself: Do you think this flushed some people out? Do you think some panic sold? Nobody, not me, not anyone, knows where the USD valuation is going. I believe it's going to go higher but all I know for sure is that where we are now...December of the halving year...is behaving, overall, quite similar to December 2020. ADAUSD skyrockets to $1.30 and then wicks down to the $0.77 range. ~~ Part 4 - The Real Parabolic Rally Cue the post-halving year which we are less than 2 weeks away from. In 2020, from the last week of December to the last week of February, ADAUSD rallies 834%. 834% in 8 weeks. And during this time, it printed 2 weekly red candles in the later half of Jan that sent the price down -34%. And then, at the start of March, it printed two more red candles that sent the price down -25%. But the rally wasn't over because the USD valuation in the Spring of 2021 was still in the low $1's. It wasn't until the second week of May that ADA hit $2 for the first time and it wasn't until late August it hit $3. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ I believe the real parabolic rally hasn't start yet. I believe that if ADAUSD behaves similarly to how it did last cycle, we're going to have an exciting next 10 weeks, a cooloff in March+April, and an exciting start to summer. There will be turbulence. There will be doubt. This is crypto, this is the nature of trading. I suspect there will be weeks after a new local high is printed that we're all down 20%-40% and that's okay, it doesn't imply the end of the cycle. ~~ This isn't financial advice and this isn't investment advice, but now that we're still in the <$1.00/ADA it's probably worth determining what you want your exit strategy to be. Good luck out there.
BINANCE:ADAUSDLong
by Varmushu
#EURCAD 2HEURCAD (2H Timeframe) Analysis Market Structure: Channel Pattern: The price is moving within a defined channel, respecting both support and resistance levels. Currently, it is near the upper boundary of the channel, signaling potential resistance. Bearish Engulfing Area: A bearish engulfing candlestick pattern has appeared near the resistance zone, indicating possible selling pressure. Forecast: Sell Opportunity: The price is positioned at the channel resistance with bearish candlestick confirmation, suggesting a potential downward move within the channel. Key Levels to Watch: Entry Zone: Near the upper boundary of the channel or at the bearish engulfing area. Risk Management: Stop Loss: Placed above the channel resistance or engulfing candle high to protect against invalidation. Take Profit Zones: Target the midline or lower boundary of the channel as potential downside levels. Market Sentiment: Bearish Outlook: Sellers are likely to dominate as long as the price remains below the resistance area, maintaining a downward channel trend.
Short
by PIPSFIGHTER
Bullish Alert: DGB's Path to 300% Gains!DigiByte (DGB) recently saw its price surge dramatically. Now, it's testing a key price level that acts as support. Think of this support level as a safety net; if the price falls below it, the drop could be more significant. Successfully holding above this support would be a positive sign for the cryptocurrency. If DGB manages to maintain its position at this support level, we believe it could lead to another significant price rise, potentially up to 300% over the medium term. A successful retest would likely encourage more buying activity, pushing the price higher and creating a bullish trend for DGB.
by TheCryptoCity
Bullish tendency is broken 101-102K for sellingMorning folks, So, BTC was not able to stay above predefined support area and drop right back to the daily 92-95K level. It means that existing bullish context on daily chart is done. In general, this is reasonable - we're going to the Xmas Holidays and inauguration. There are a lot of uncertainty with coming D. Trump policy. Especially when JPowell said that the Fed doesn't intend to own any BTC... so inner conflict is ready. So, retracement might be deeper in nearest month. Since BTC is overextended down a bit, the first thing we expect upside technical bounce, somewhere to 101-102K area. Then, if we're correct in our analysis, downside reversal should happen with potential H&S pattern.
COINBASE:BTCUSDShort
by Sive-Morten
CHFJPY Trading Opportunity! SELL! My dear subscribers, CHFJPY looks like it will make a good move, and here are the details: The market is trading on 174.84 pivot level. Bias - Bearish My Stop Loss - 175.91 Technical Indicators: Both Super Trend & Pivot HL indicate a highly probable Bearish continuation. Target - 172.92 About Used Indicators: The average true range (ATR) plays an important role in 'Supertrend' as the indicator uses ATR to calculate its value. The ATR indicator signals the degree of price volatility. ——————————— WISH YOU ALL LUCK
Short
by AnabelSignals
1
AAPL Technical Analysis for Tomorrows - Dec.23 1. 1-Hour Timeframe * Current Price: $255.28 * Resistance Levels: * $257.30 (recent high and breakout level) * $260.00 (psychological level and potential target) * Support Levels: * $251.97 (previous breakout zone, now acting as support) * $249.79 (secondary key support level) 2. Key Observations A. Trend and Momentum: * AAPL recently broke out of a descending trendline with strong momentum, signaling bullish strength. * Price action is currently consolidating just below the resistance at $257.30, which will be critical for determining the next move. B. Stochastic Oscillator: * The Stochastic is nearing the overbought zone, suggesting that the stock might see a slight pullback before making another attempt to move higher. C. Volume Analysis: * The breakout was accompanied by a noticeable volume spike, validating the bullish breakout. However, sustained volume will be needed to push past $257.30. 3. Trade Scenarios Bullish Scenario: * Entry: Look for consolidation above $255.00, followed by a breakout of $257.30 with strong volume. * Target: $260.00 (psychological resistance) and potentially higher if momentum sustains. * Stop-Loss: Below $251.97 to limit downside risk. Bearish Scenario: * Entry: If AAPL rejects $257.30 and breaks below $251.97 with increasing volume. * Target: $249.79 (key support zone) and possibly lower. * Stop-Loss: Above $257.30. 4. My Thoughts on AAPL’s Direction Based on the current price action and volume dynamics, I believe AAPL is more likely to test the $257.30 resistance and break higher. The bullish breakout from the descending trendline, combined with strong volume, supports upward momentum. However, with the Stochastic Oscillator nearing overbought levels, we could see a brief pullback before further upside. If $257.30 is broken decisively, $260.00 becomes a realistic short-term target. 5. Key Levels to Watch * Support: $251.97 and $249.79 * Resistance: $257.30 and $260.00 AAPL is displaying strong bullish momentum, and my bias is tilted toward the upside for tomorrow. Keep an eye on the $257.30 resistance level for a breakout or rejection, as this will dictate the next move. Disclaimer: This analysis is for educational purposes only and does not constitute financial advice. Please trade responsibly and manage your risk accordingly. -------------- Scalping Strategy (Options Trading) Key Observations: * Resistance Levels: * $257.50: Highest Gamma Wall, acting as a strong resistance. * $260.00: Psychological and GEX resistance zone. * Support Levels: * $252.50: 3rd Call Wall (moderate support). * $247.50: HVL (High Volume Level), a major support. Scalping Call Options: * Setup: Enter calls if price consolidates above $257.50 and breaks out with volume confirmation. * Exit Target: $260.00. * Stop-Loss: Below $257.00 to minimize risk. Scalping Put Options: * Setup: Enter puts if the price rejects $257.50 or fails to hold above $257.00. * Exit Target: $252.50. * Stop-Loss: Above $258.00. Long/Short Strategy Long Strategy: * Entry: Look for a breakout above $257.50 with strong volume and bullish momentum. * Target: $260.00 (short-term), $262.50 (extended target). * Stop-Loss: Below $256.00 to protect against reversal. Why It Works: * $257.50 is the highest gamma exposure level, and a breakout above this zone indicates strong bullish sentiment. Short Strategy: * Entry: Enter short positions if the price fails to break above $257.50 and shows a rejection (e.g., wicks or bearish engulfing candles). * Target: $252.50 (3rd Call Wall), $247.50 (HVL). * Stop-Loss: Above $258.00. Why It Works: * Rejection at $257.50 confirms resistance and potential profit-taking, aligning with put gamma levels below $252.50. Key Tips for Scalping and Options Trading 1. Volume Confirmation: * Ensure volume spikes during breakouts or rejections for higher probability trades. 2. Timeframe: * Use the 1-minute or 5-minute chart for scalping execution. 3. Implied Volatility: * IV is at 24.1%. Look for slightly out-of-the-money (OTM) options with low time decay for scalping. Conclusion * Bullish Case: AAPL breaks above $257.50 → Target $260.00 and $262.50. * Bearish Case: AAPL rejects $257.50 → Target $252.50 and $247.50. Stay focused on high-probability setups by watching volume, price action near key levels, and momentum indicators like Stochastic Oscillator. Let me know if you'd like a more specific strike price or expiration recommendation! 🚀
NASDAQ:AAPL
by BullBearInsights
1
BPTH could be in for a bull market in 2025!One new low cap stock pick with my research described below, please do your own research aswell and remember these are risky moves - thus small allocation. I will be back with many crypto charts for next year as well, don't worry! Bio-Path Holdings (BPTH) Overview: Bio-Path Holdings, Inc. is a biotechnology company focused on developing nucleic acid cancer drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology. This technology allows for the development of drugs that can be administered through intravenous transfusion, targeting specific genes associated with cancer. Last week, Bio-Path Holdings announced preclinical results for their drug candidate BP1001-A. The study demonstrated that BP1001-A enhances insulin sensitivity, suggesting its potential as a treatment for obesity in patients with Type 2 diabetes. In 2025, Bio-Path Holdings plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A, focusing on validating its safety, measuring pharmacokinetics, and establishing dosing for potential pivotal trials. This trial is aimed at further exploring BP1001-A's potential as a treatment for obesity and related metabolic diseases in patients with Type 2 diabetes. A successful trial would likely lead to a significant increase in Bio-Path Holdings' stock price. The news of positive clinical results would be seen as a validation of the drug's potential, attracting more investor interest and possibly leading to partnerships or buyouts from larger pharmaceutical companies. SPECULATION: Estimating the yearly revenue potential and a fair valuation for Bio-Path Holdings (BPTH) based on BP1001-A's market entry involves several speculative assumptions, as we lack specific data on market penetration, pricing, competition, and long-term efficacy. Here's a theoretical breakdown: Revenue Potential: Market Size and Share: Obesity and Type 2 Diabetes Market: The global market for treatments of obesity and Type 2 diabetes is substantial. For context, the global diabetes market alone was valued at approximately $51.1 billion in 2022, expected to reach $81.6 billion by 2030, growing at a CAGR of around 6.5% (). However, BP1001-A would be competing in a segment of this market focused on novel treatments or those with a unique mechanism like insulin sensitivity enhancement. Assumed Market Share: Assuming BP1001-A captures a niche segment, let's speculate it achieves a 1% to 5% market share due to its novel mode of action and targeting a specific subset of Type 2 diabetes patients with obesity. Pricing and Usage: Drug Pricing: New diabetes drugs, especially those with innovative mechanisms, can be priced high. For instance, if we assume a yearly cost per patient of $10,000 (considering the high cost of biologics and similar therapies), Patient Population: If we estimate that 1% of the diabetic population globally (approximately 537 million adults in 2021 according to IDF) could benefit from this drug, that's about 5.37 million patients. At 5% market share, this would mean 268,500 patients. Revenue Calculation: Annual Revenue: If 268,500 patients use BP1001-A at $10,000 per year, the potential annual revenue would be approximately $2.685 billion. For a 1% market share (53,700 patients), it would be around $537 million. Valuation: DCF Approach: A Discounted Cash Flow (DCF) analysis would be the traditional method to value BPTH if BP1001-A were to generate such revenues. Here's a simplified speculative approach: Cash Flow: Assuming 50% of revenue translates into gross profit (considering R&D, marketing, and other costs), a 1% market share would yield $268.5 million in gross profit, and 5% would yield $1.3425 billion. Discount Rate: Biotech companies often have high discount rates due to risk. Let's assume a 15% discount rate for this speculative valuation. Growth & Terminal Value: Assume growth stabilizes after initial high growth years, with a terminal growth rate of 2% post-patent exclusivity period (which might be around 20 years from patent to market). Valuation Calculation: With a 1% market share scenario: Present Value of Cash Flows for first 10 years (assuming rapid growth then stabilization): $268.5M * Annuity Factor at 15% = $1.4 billion (very roughly). Terminal Value (Gordon Growth Model) = $268.5M * (1+0.02)/(0.15-0.02) = $2.14 billion. Total Equity Value = PV of cash flows + Terminal Value = $3.54 billion. With a 5% market share scenario: Present Value of Cash Flows for first 10 years: $1.3425B * Annuity Factor at 15% = $7 billion (again, very roughly). Terminal Value = $1.3425B * (1+0.02)/(0.15-0.02) = $10.7 billion. Total Equity Value = $17.7 billion. Market Multiples: If we use industry multiples (PE ratios for biotech can be very high, especially for novel treatments), with a PE ratio of 20-30 for a company with significant growth potential, the valuation based on earnings from BP1001-A alone would range from: 1% Market Share: $5.37 billion (20 * $268.5M) to $8.055 billion (30 * $268.5M). 5% Market Share: $26.85 billion (20 * $1.3425B) to $40.275 billion (30 * $1.3425B). Fair Valuation: Given these speculative numbers, a fair valuation for BPTH based solely on BP1001-A's potential would be somewhere in the middle of these ranges, adjusted for the company's current financials, other pipeline drugs, and market conditions. Considering the above, a conservative estimate might place BPTH's valuation in the range of $3 billion to $10 billion, depending on market penetration optimism, with the understanding that this is highly speculative and subject to countless variables including regulatory approval, actual market acceptance, and competitive landscape. CONCLUSION & TA: This simply means, IF(!) this drug is succesfull the market cap of this company would significantly rise. Currently we're sitting at a 5.43 million market cap (at close, so lower now), thus its a 100 to 1000x potential or it drops to zero. Last note, price needs to stay above $1 to stay compliant with Nasdaq rules or else there could be an inverse stock split 2 to 1 for example or they face delisting by the end of Q3 2025. I'm not too worried because this is the same as SEALSQ faced before it 10x'd in the last few weeks. TA wise: we're retesting previous resistance and the bull market support band. Chart has been down only for years, capitulation after capitulation thus chance of a rebound should be there. I grabbed a small allocation to sit out for 2025, if the clinical trials are successful, we'll in for a big bull market. If not succesfull, we'll likely lose our money. A very decent risk / reward ratio of you invest an amount you can afford to lose and not more than 5% of your portfolio. This is one of my low cap stock picks, next to LAES (10x since entry) and MOBX (entry last week, flat pa for now). I will be scouting for more but for now, happy holidays!
NASDAQ:BPTHLong
by cryptobullethbtcxlm
APTUSDT Technical Analysis: Risk-Reward Setup with Dynamic Sp.LvRisk: %17 | Reward: %45 and beyond APTUSDT is exhibiting signs of potential price movement with significant technical indicators supporting the analysis. A noticeable bullish divergence on RSI and a temporary retracement towards a key support level may provide an ideal opportunity for long positions. Traders are advised to watch price action closely around the identified trendline and support zones for entry confirmations. Trading suggestion: A possible retracement to the $8.37 support line might occur. Traders can consider setting buy orders based on price action confirmation near the suggested support and aim for mid to long-term targets. Technical analysis: The RSI is oversold, indicating potential upside momentum if the trendline is respected. The DMF Index shows declining bearish pressure, hinting at a reversal possibility. SL = Break below $6.91 support zone. This setup offers a favorable risk-to-reward ratio with dynamic levels to monitor. Always trade with proper risk management strategies.
Long
by srmustafabas
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market price (CMP) near a double-bottom structure, a second purchase around the $138–$136 range (61.8% Fibonacci level), and a third at the $133–$135 channel bottom. A stop loss is defined at $130 on a closing basis to manage downside risk, emphasizing disciplined trading within the defined channel boundaries.
NYSE:JNJLong
by jayshafiq2
Bullish Silver TradeThe silver market appears poised for a bullish move, supported by weekly institutional buying levels. On the daily chart, the price has retraced approximately 71%, offering a favorable discount for long positions. This level aligns with a classic retracement zone, suggesting strong potential for a reversal to the upside. Traders can aim for an initial take-profit target at the 127% Fibonacci extension, which represents a common projection for price continuation following a retracement.
OANDA:XAGUSD
by NyukiForexTrader
Tesla - Breakout level re-test complete. Could launch from hereHello Traders. Looking at Tesla you can see many things that show Tesla is positioned to launch from here. 1.Previous times on the 2Hr since November when the 20/50 EMA crossed(DeathCross) Tesla went up shortly thereafter. It just crossed again. 2. Tesla recently broke out from ATH... but in the last few days came back down in a much needed cooling off and retested the breakout price and has bounced. This is MEGA bullish in my book. 3. You can clearly see an inverse Head & shoulder as well... 4. Bounced off the 2h 100EMA and Monthly VWAP. So without even showing other indicators ,which agree as well, You can clearly see Tesla is positioned for another mega bullish run. We could see 500+ by end of Christmas week.. and it heading even higher into the new year.
NASDAQ:TSLALong
by TheUniverse618